Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium (177Lu) rhPSMA-10.1 in advanced metastatic castration-resistant prostate cancer
NL-OMON60058Phase 2Recruiting
- Sponsor
- Blue Earth Therapeutics
- Start
- Feb 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium (177Lu) rhPSMA-10.1 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Blue Earth Therapeutics. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
lutetium (177Lu) rhPSMA-10.1
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60058.